There have been very few new therapies in the critical care arena over the past half century. Ikaria is committed to changing that.
We use our scientific expertise to develop biotherapeutic solutions for the critical care market. Our research continues to break new ground toward our goal of improving the clinical outcomes for critically ill patients. INOMAX® (nitric oxide) for inhalation is our first commercialized product and it demonstrates our ability to develop therapies that meet the significant needs of these patients.
INOMAX is a registered trademark of INO Therapeutics LLC.
Chief Science Officer
Martin Meglasson, PhD, joined Ikaria, Inc. in 2010 as Chief Science Officer. Dr Meglasson is responsible for activities related to early-stage drug development. With over 20 years of experience in the pharmaceutical industry, Dr Meglasson joined Ikaria from Ligand Pharmaceuticals Incorporated, where he was Vice President of Discovery Research. Prior to his tenure at Ligand, he held several leadership positions at Pharmacia Inc. and its predecessor companies, Pharmacia & Upjohn and the Upjohn Company. Dr Meglasson has participated in the discovery and development of two marketed drugs, and is an inventor of 18 US patents.